Financial reports
20-F
2023 FY
Annual report (foreign)
24 Oct 23
20-F
2022 FY
Annual report (foreign)
31 Oct 22
20-F
2021 FY
Annual report (foreign)
25 Oct 21
20-F
2020 FY
Annual report (foreign)
25 Sep 20
20-F
2019 FY
Annual report (foreign)
23 Sep 19
20-F
2018 FY
Annual report (foreign)
19 Oct 18
20-F
2017 FY
Annual report (foreign)
19 Oct 17
20-F/A
2016 FY
Annual report (foreign) (amended)
28 Jun 17
20-F
2016 FY
Annual report (foreign)
3 Oct 16
20-F
2015 FY
Annual report (foreign)
30 Oct 15
Current reports
6-K
Immutep Announces Positive Preliminary Topline Results from
24 Apr 24
6-K
Immutep Appoints Leading Research Institute to Conduct
18 Apr 24
6-K
Immutep Announces First Clinical Data from 90mg Dosing of Efti
6 Mar 24
6-K
Half-Year Financial Report
29 Feb 24
6-K
Immutep Quarterly Activities Report & Appendix 4C
30 Jan 24
6-K
Immutep Receives Constructive Regulatory Feedback on TACTI-004
21 Dec 23
6-K
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
7 Dec 23
6-K
Current report (foreign)
9 Nov 23
6-K
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
6 Nov 23
6-K
Immutep Announces New Biomarker Data from TACTI-002 Phase II
3 Nov 23
Registration and prospectus
F-3
Shelf registration (foreign)
28 Apr 23
F-3
Shelf registration (foreign)
15 Oct 19
D
$520.67K in equity, sold $520.67K, 4 investors
30 Jul 19
424B3
Prospectus supplement
14 Feb 19
F-3
Shelf registration (foreign)
14 Jan 19
D
$5.2M in options / securities to be acquired, sold $5.2M, 2 investors
21 Dec 18
424B5
Prospectus supplement for primary offering
19 Dec 18
F-3
Shelf registration (foreign)
19 Oct 17
D
$5M in options / securities to be acquired, sold $5M, 6 investors
14 Jul 17
424B5
Prospectus supplement for primary offering
30 Jun 17
Proxies
No filings
Other
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
UPLOAD
Letter from SEC
2 May 23
EFFECT
Notice of effectiveness
31 Oct 19
CORRESP
Correspondence with SEC
28 Oct 19
UPLOAD
Letter from SEC
22 Oct 19
EFFECT
Notice of effectiveness
12 Feb 19
CORRESP
Correspondence with SEC
8 Feb 19
UPLOAD
Letter from SEC
8 Feb 19
CT ORDER
Confidential treatment order
16 Nov 18